|
|
Article: AstraZeneca and Mental Health Research Institute in Australia Announce Collaboration to Improve Early Detection of Alzheimer's Disease.
- Article from:
- Biotech Week
- Article date:
- July 29, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
AstraZeneca and The Mental Health Research Institute in Melbourne, Australia, announced that they have entered into a research collaboration agreement to develop new ways of identifying Alzheimer's disease patients at early stages of the disease (see also Mental Health).
Researchers aim to find out whether testing cognition at short intervals (every one to three months) over an eighteen-month period will make it possible to identify individuals just at the point at which they are beginning to suffer cognitive decline as a result of Alzheimer's disease.
The study will be conducted in conjunction with The Australian Imaging, Biomarker & Lifestyle Flagship ...
Related newspaper, magazine, and journal articles:
|